Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study Meeting Abstract
| Authors: | Flowers, C.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y. Q.; Greil, R.; Mykhalska, L.; Bergua-Burgués, J. M.; Cheung, M. C.; Pinto, A.; Shin, H. J.; Hapgood, G.; Munhoz, E.; Abrisqueta, P.; Gau, J. P.; Hirata, J.; Jiang, Y.; Yan, M.; Lee, C.; Salles, G. |
| Abstract Title: | Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | treatment; diffuse large b-cell lymphoma; phase iii; first-line; r-chop; polatuzumab vedotin; abcl |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S358 |
| End Page: | S359 |
| Language: | English |
| ACCESSION: | WOS:000897948100377 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01498-7 |
| Notes: | Meeting Abstract: ABCL-073-- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work